Opendata, web and dolomites

Curtana

Patented small molecule therapeutics that target cancer stem cells for the treatment of glioblastoma and other brain cancers

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 Curtana project word cloud

Explore the words cloud of the Curtana project. It provides you a very rough idea of what is the project "Curtana" about.

survival    deadliest    lung    tolerated    crosses    malignant    killing    median    13    ct    rate    curtana    molecule    too    primary    therapies    14    diagnosed    standard    investors    45    stem    drug    blood    approval    centre    bulk    offers    gliomas    worldwide    people    bioavailable    conventional    nervous    accounting    progression    orally    cells    drive    clinical    brain    expansion    small    trials    80    tumour    care    tumorigenesis    index    patients       months    inhibiting    cytotoxic    diagnoses    hope    68    indicate    drugs    endometrial    answer    radiosensitiser    relative    potent    ineffective    die    identification    therapeutic    cancers    treatment    cure    central    instrumental    benefit    olig2    cancer    255    tumours    barrier    most    improvement    ovarian    179    marketing    glioblastoma    reduce    aggressive    found    biggest    transcription    compound    little    killer    feasibility    kills    over    rates    expressed   

Project "Curtana" data sheet

The following table provides information about the project.

Coordinator
CURTANA PHARMA LTD 

Organization address
address: 72 GREAT SUFFOLK STREET
city: LONDON
postcode: SE1 0BL
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country United Kingdom [UK]
 Project website http://www.curtanapharma.com/
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-1-2016-2017
 Funding Scheme SME-1
 Starting year 2017
 Duration (year-month-day) from 2017-02-01   to  2017-05-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    CURTANA PHARMA LTD UK (LONDON) coordinator 50˙000.00

Map

 Project objective

Over 45,000 people die each year in Europe – and 255,000 worldwide – from cancers of the brain and central nervous system. Gliomas are the biggest killer, accounting for a third of all diagnoses and 80% of primary malignant brain tumours. Among these glioblastoma is the most common, most aggressive and deadliest. Standard of care treatment offers little hope for patients diagnosed with gliomas: there is no cure, the median survival is 14.6 months and the 2-year survival rate is 13.5%. Conventional therapies can reduce tumour bulk, but they are ineffective at killing the cancer stem cells that drive tumour progression. Curtana may have found the answer. Its novel approach targets a transcription factor, Olig2, which is instrumental in tumorigenesis, tumour expansion and survival. By inhibiting Olig2, Curtana’s small molecule compound, CT-179, kills cancer stem cells. Pre-clinical results show CT-179 to be cytotoxic in selected tumours, a potent radiosensitiser, orally bioavailable and well tolerated; it also crosses the blood-brain barrier and has a high therapeutic index relative to conventional cancer drugs. Most importantly, it increases survival rates (in early studies, median improvement was 68%). Results indicate it may have benefit for other cancers too – any in which Olig2 is highly expressed, including all gliomas and other cancers such as lung, ovarian and endometrial. The Phase 1 project will address the feasibility of carrying out the further pre-clinical and clinical studies required before Curtana can apply for drug marketing approval. This will include identification of clinical partners for multi-centre trials that would be carried out in Europe in Phase 2, as well as potential investors.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "CURTANA" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "CURTANA" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

AutoCRAT (2020)

Automated Cellular Robot-Assisted Technologies for translation of discovery-led research in Osteoarthritis

Read More  

LEGACy (2019)

CeLac and European consortium for a personalized medicine approach to Gastric Cancer

Read More  

VANGUARD (2020)

New Generation Cell Therapy: Bioartificial Pancreas to Cure Type 1 Diabetes

Read More